Your SlideShare is downloading. ×
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Neuroprotective Agents To Reduce Neuronal Loss Following Sci

401

Published on

Presentation of research project at the Open University.

Presentation of research project at the Open University.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
401
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • e.g. compression of neural element after vascular damage (double the size of the primary) Secondary injury is initiated by primary injury s
  • Spinal cord lesion in rats. Cytokines are also involved – they trigger apoptosis Cellular components such as neutrophils, once at the site of injury, secrete cytokines and lytic enzymes
  • Mention Ally started all this work First: make gels. Then: stimuli... Glutamate is the main agonist Glycine: co-agonist
  • Microscope: 2 fluorescent filters
  • How quickly cells die – apoptosis/necrosis? compare cell death with other stimuli see PRARIY in cells protective activity? optimal dose of PRARIY Control
  • w/o FCS gels had better response to glutamate Longer incubation times – literature search Glutamate treated gels had less cells – response may be greater than seen
  • Say what things are e.g. FITC PRARIY is green... In figure 4 (A), peptide around the nucleus, bright green disc caveolae? Further investigation The CM DiI (red) shows the cytoplasm; green PRARIY in the cytosol Peptide is cytoplasmic, proving it enters the cell
  • reducing cell death by 27% This is still a work in progress
  • Glutamate vs 20 ug *; Glutamate vs 200 ng **; Glutamate vs 20 ng **;
  • At most doses... Not 20 ug
  • Others have used PRARI as the negative control
  • PRARIY results – rough estimates at the moment Time limitation... Ally also saw this neuroprotection
  • Some time between 6 and 24? Monitor cell viability after gels are set and throughout experiments. Investigate different cell culture media Then repeat the experiments outlined in the refined model and investigate the mechanism of PRARIY Question – delivery in human? Peptide implants that release the peptide. Investigate the mechanism and find the target... Question – concentration of glutamate in vivo? I used higher concentrations, there weren’t all the other stimuli etc Question – current treatments of SCI? Anti-inflammatory drugs + surgery to stabilise the patient
  • Transcript

    • 1. Annabel Ola 15.9.2011
    • 2. Spinal Cord Injury (SCI)
      • Traumatic insult to the spinal cord causes mechanical damage and tissue degeneration
      • Primary injury:
          • Mechanical trauma
          • Spinal cord swells, filling spinal canal
          • Necrosis
      • Secondary injury:
          • Ischaemia and apoptosis
          • The site of injury is expanded
          • Therapeutic benefit would be stopping this process
    • 3. Background to this project
      • Neuroprotective action of fibronectin peptides (2010 King et al.)
      • The peptide PRARIY decreased neuronal death in vivo .
      Proline Arginine Alanine Arginine Isoleucine Tyrosine
    • 4. Aims and objectives
      • Aim : To investigate the activity of PRARIY in an in vitro model of spinal cord injury
      • Objectives :
      • Set up a culture system to investigate neuronal cell death.
      • Characterise the uptake and localisation of fluorescently labelled peptide PRARIY in neuronal cells.
        • Is this peptide protective?
        • Where is the peptide localised?
      • Compare neuroprotection seen with PRARIY to a scrambled control peptide YRPIRA, to investigate whether it is this particular sequence of amino acids in the peptide which confers the neuroprotective characteristics.
    • 5. Approaches to creating a model of cell death in vitro
      • 3D cell culture of 2 neuronal cell lines
          • Pure neuronal cultures
          • More reproducible than primary cultures
          • Traps the cells in collagen matrix/scaffold
          • Viability was assessed before setting in gels
      • 10 mM Glutamate & 50 µM Glycine
          • Act on NMDA receptors and induce excitotoxicity
          • Glycine is a co-agonist of the NMDA receptor
    • 6. Approaches to creating a model of cell death in vitro (2)
      • Other stimuli – induce cell death in the CNS
          • 1 μg/mL TNF α – inflammatory stimulus
          • 100 mM NMDA – excitotoxic stimulus
      • Live/dead staining
          • 200 μg/mL Propidium iodide
              • Red stain for dead cells
          • 1 μg/mL Hoechst
              • Blue stain for all cells regardless of viability
    • 7. Approaches to creating a model of cell death in vitro
          • Figure 1 . Examples of staining with 200 μg/mL Propidium iodide (A) and 1 μg/mL Hoechst (B) in live/dead staining of collagen gels.
      B A
    • 8. Optimising treatment protocol
    • 9. Overview of experiments
      • Time course death experiment
      • Excitotoxic/inflammatory stimuli comparison
      • PRARIY localisation
      • PRARIY rescue from death by glutamate
      • Dose-dependent effect of PRARIY
      • Comparison of PRARIY and scrambled peptide YRPIRA
    • 10. Time course death of B104 cells Differences in death were seen between control and treated gels, shown in figure 2 with the optimised protocol. At 24 and 48 hours, there were significant differences between control and treated. *** ***
    • 11. Excitotoxic and inflammatory stimuli comparison – B104 Similar amounts of death were elicited by each of the stimuli. Cell death was seen with and without the presence of FCS. More death was seen without, so this was chosen as the treatment vehicle.
    • 12. PRARIY localisation in B104 2D culture FITC-PRARIY entered the B104 cells. The peptide is largely cytoplasmic (figure 4 A and C), creating an orange colour with the co-localisation of the CM DiI. D Figure 4. B104 24hr Fluorescent peptide uptake. Hoechst with FITC-PRARIY (A), FITC-PRARIY only (B), an overlay of 3 images (C) and FITC-PRARIY with CM DiI (D). A B C D
    • 13. PRARIY rescue of B104 cells PRARIY with glutamate had a significant effect on the amount of cell death by glutamate at 24 hours, but the level of death in the control was very high. *** ***
    • 14. Dose response of B104 cells to PRARIY There was no dose-dependent effect seen with B104 cells but there were significant differences between glutamate treated gels and the different doses of the peptide. There could however be a dose-dependent effect with lower doses and further investigation is needed. * ** **
    • 15. Dose response of NG108 cells to PRARIY Again there was no dose-dependent effect seen in NG108 cells, but PRARIY brought the levels of death to that seen in the control. This is the only NG108 experiment where the control levels of death has been significantly lower than that seen with glutamate. ** *** *** *
    • 16. Initial comparison of PRARIY and YRPIRA No difference between the two peptides but both reduced glutamate levels of death however glutamate levels of death were not high. More investigation is needed but there was limited time to repeat these experiments etc. *** ***
    • 17. Scrambled peptide YRPIRA elicits protection in NG108 cells There was a significant difference between the two peptides (n=4, P<0.05). Also PRARIY and YRPIRA significantly reduced cell death. And again control levels of death were lower than previously seen. ** *** *
    • 18. Conclusions
      • There was variability between experiments, especially with the NG108 cells.
      • I could not properly investigate what I had set out to and results were inconclusive.
      • PRARIY enters B104 and NG108 cells.
      • PRARIY appears to reduce levels of death elicited with glutamate.
    • 19. Future experiments
      • Improve the cell death model to isolate cells so there is less variability between experiments.
      • Establish a full time course death experiment.
      • Peptide rescue in cell death caused by other stimuli.
      • Investigate the localisation of PRARIY at different time points
    • 20. Acknowledgements
      • The Open University - Dr James Phillips, Dr John Golding, Dr Jane Loughlin and Melanie Georgiou
      • The School of Pharmacy - Dr Rosemary Smyth and Dr Mike Munday
    • 21. Thank you for listening
      • Questions?

    ×